BMO Capital Markets maintained its "Outperform" rating on Tourmaline Bio, Inc. with a price target of $35, citing the market's overreaction to Phase II data for Paci. Despite concerns, BMO believes Paci's quarterly treatment could outperform competitors.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing